A phase II trial revealed that a low overexpression rate of HER-2 (8.0%) in advanced CRC limits the application of Herceptin as a treatment for advanced-stage CRC; however, partial responses were observed in five of the seven evaluable patients (17). This evidence concerns the gene ERBB2 and colorectal carcinoma.